What Happened
According to a report, Robert F. Kennedy Jr. has proposed that the U.S. Food and Drug Administration (FDA) allow unproven peptides to proceed without standard regulatory enforcement.
Key Details
- FDA scientists maintain that none of the popular peptide treatments in question have been proven safe or effective.
- The proposal advocates for relaxing regulatory scrutiny over these unproven substances.
What Remains Unknown
Due to limited source metadata, specific policy mechanics, formal FDA responses, and potential regulatory timelines remain unverified.
